United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - hydrochlorothiazide 12.5 mg - hydrochlorothiazide is indicated in the management of hypertension either as the sole therapeutic agent, or in combination with other antihypertensives. unlike potassium sparing combination diuretic products, hydrochlorothiazide may be used in those patients in whom the development of hyperkalemia cannot be risked, including patients taking ace inhibitors. usage in pregnancy: the routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developed toxemia. edema during pregnancy may arise from pathological causes or from the physiologic and mechanical consequences of pregnancy. diuretics are indicated in pregnancy when edema is due to pathologic causes, just as they are in the absence of pregnancy. dependent edema in pregnancy resulting from restriction of venous return by the expanded uterus is properly t

United States - English - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - hydrochlorothiazide 12.5 mg - hydrochlorothiazide capsules are indicated in the management of hypertension either as the sole therapeutic agent, or in combination with other antihypertensives. unlike potassium sparing combination diuretic products, hydrochlorothiazide may be used in those patients in whom the development of hyperkalemia cannot be risked, including patients taking ace inhibitors. usage in pregnancy the routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developed toxemia. edema during pregnancy may arise from pathological causes or from the physiologic and mechanical consequences of pregnancy. diuretics are indicated in pregnancy when edema is due to pathologic causes, just as they are in the absence of pregnancy. dependent edema in pregnancy resulting from restriction of venous return by the expanded uterus is pr

United States - English - NLM (National Library of Medicine)

heritage pharmaceuticals inc. - hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - hydrochlorothiazide 12.5 mg - hydrochlorothiazide tablets are indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. hydrochlorothiazide tablets have also been found useful in edema due to various forms of renal dysfunction such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. hydrochlorothiazide tablets are indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension. routine use of diuretics during normal pregnancy is inappropriate and exposes mother and fetus to unnecessary hazard. diuretics do not prevent development of toxemia of pregnancy and there is no satisfactory evidence that they are useful in the treatment of toxemia. edema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy. thiazides are indicated in pregnancy when edema is du

United States - English - NLM (National Library of Medicine)

heritage pharmaceuticals inc - hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th) - hydrochlorothiazide 12.5 mg - hydrochlorothiazide capsules are indicated in the management of hypertension either as the sole therapeutic agent, or in combination with other antihypertensives. unlike potassium sparing combination diuretic products, hydrochlorothiazide capsules may be used in those patients in whom the development of hyperkalemia cannot be risked, including patients taking ace inhibitors. usage in pregnancy: the routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developed toxemia. edema during pregnancy may arise from pathological causes or from the physiologic and mechanical consequences of pregnancy. diuretics are indicated in pregnancy when edema is due to pathologic causes, just as they are in the absence of pregnancy. dependent edema in pregnancy resulting from restriction of venous return by the expanded ut

Australia - English - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - hydrochlorothiazide, quantity: 12.5 mg; amlodipine besilate, quantity: 13.888 mg (equivalent: amlodipine, qty mg); olmesartan medoxomil, quantity: 40 mg - tablet - excipient ingredients: pregelatinised maize starch; microcrystalline cellulose; magnesium stearate; croscarmellose sodium; colloidal anhydrous silica; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350 - sevikar hct is indicated for the treatment of hypertension, either as replacement for olmesartan medoxomil, amlodipine and hydrochlorothiazide being already taken as separate tablets or as add-on therapy where a patient's blood pressure is not controlled on a dual combination (see dosage and administration). this fixed dose combination is not indicated for initial therapy

New Zealand - English - Medsafe (Medicines Safety Authority)

apotex nz ltd - cilazapril monohydrate 5.22mg equivalent to 5 mg cilazapril base; hydrochlorothiazide 12.5mg - film coated tablet - 5 mg/12.5 mg - active: cilazapril monohydrate 5.22mg equivalent to 5 mg cilazapril base hydrochlorothiazide 12.5mg excipient: hyprolose hypromellose iron oxide red macrogol 8000 maize starch microcrystalline cellulose sodium stearyl fumarate titanium dioxide - apo-cilazapril/hctz is indicated for the treatment of patients with hypertension who are not adequately controlled on monotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - hydrochlorothiazide, quantity: 12.5 mg; eprosartan mesilate, quantity: 735.8 mg (equivalent: eprosartan, qty 600 mg) - tablet, film coated - excipient ingredients: crospovidone; microcrystalline cellulose; lactose monohydrate; magnesium stearate; pregelatinised maize starch; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350; iron oxide black - teveten plus is indicated for the treatment of hypertension. treatment should not be initiated with this fixed dose combination.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

milpharm ltd - hydrochlorothiazide; losartan potassium - oral tablet - 12.5mg ; 100mg

New Zealand - English - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - hydrochlorothiazide 12.5mg;  ;  ; losartan potassium 50mg;   - film coated tablet - 50mg/12.5mg - active: hydrochlorothiazide 12.5mg     losartan potassium 50mg   excipient: carnauba wax hyprolose hypromellose lactose monohydrate magnesium stearate microcrystalline cellulose quinoline yellow starch titanium dioxide - hypertension hyzaar is indicated for the treatment of hypertension, for patients in whom combination therapy is appropriate. reduction in the risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy hyzaar is a combination of losartan (cozaar) and hydrochlorothiazide. in patients with hypertension and left ventricular hypertrophy, losartan, often in combination with hydrochlorothiazide, reduces the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death, stroke, and myocardial infarction in hypertensive patients with left ventricular hypertrophy.

New Zealand - English - Medsafe (Medicines Safety Authority)

boucher & muir (new zealand) limited t/a bnm group - hydrochlorothiazide 12.5mg; losartan potassium 50mg - film coated tablet - 50mg/12.5mg - active: hydrochlorothiazide 12.5mg losartan potassium 50mg excipient: hypromellose lactose monohydrate macrogol 4000 magnesium stearate microcrystalline cellulose pregelatinised maize starch purified talc quinoline yellow titanium dioxide - losartan hctad is indicated for the treatment of hypertension, for patients in whom combination therapy is appropriate.